Fibrillary astrocytomas are the most common type of diffuse low grade astrocytoma and as of the 2016 update to WHO classification of CNS tumours it no longer exists as a distinct entity, having been incorporated into the generic term diffuse astrocytoma 6.
Unlike the other variants of diffuse low grade gliomas (e.g. gemistocytic astrocytoma, protoplasmic astrocytoma, oligoastrocytoma) or the focal low grade gliomas (e.g. pilocytic astrocytoma, subependymal giant cell astrocytoma) they are often merely referred to as a low grade glioma.
Typically patients diagnosed with low grade infiltrative astrocytomas are young adults (mean 35 years of age) 1. A male predilection is described (M:F ~1.5:1) 1.
The most common presenting feature (~40% of cases) is seizures. This is particularly the case in adults. Headaches are often also present. Depending on the size of the lesion and its location other features may be present, e.g. hydrocephalus, focal neurological dysfunction including personality change.
The fibrillary astrocytomas are predominantly composed of a tumour matrix rich with neuroglial fibrils, which give the tumour its name and firm consistency 4. Within the tumour matrix are embedded neoplastic fibrillary astrocytes with mild nuclear atypia (enlarged, irregular contour, hyperchromasia and coarsened nuclear chromatin pattern) and a low cellular density 2-3. The nuclei are elongated and appear "naked" 4.
Often microcystic spaces containing mucinous fluid are present 2,5. Mitoses, microvascular proliferation and necrosis are absent (if present they suggest a high grade tumour). Like all tumours derived from astrocytes, fibrillary astrocytomas stain with glial fibrillary acidic protein (gFAP) 2-3.
MRI is the modality of choice for characterising these lesions, and in the case of smaller tumours, they may be subtle and difficult to see on CT, especially as they tend not to enhance.
Typically fibrillary low grade infiltrating astrocytomas appear as isodense or hypodense regions of positive mass effect, usually without any enhancement (in fact presence of enhancement would suggest high grade, e.g. WHO III or IV tumours.
Calcification is infrequently seen (10-20% of cases) 1 but is more common in mixed tumours relating to an oligodendroglial components (i.e. oligoastrocytoma).
Cystic or fluid attenuation components are also encountered although this is far more common in gemistocytic and protoplasmic variants.
- T1: isointense to hypointense compared to white matter
- T2: hyperintense
- T1 C+ (Gd): usually little or no enhancement
- MR spectroscopy: elevated choline:creatine ratio
- MR perfusion: no elevation of rCBV
Treatment and prognosis
Treatment depends on clinical presentation, size of the tumour and location. In general the options are:
- biopsy to confirm diagnosis and observe
- chemotherapy may have a role in recurrent/de-differentiated tumours
- 1. Tonn J, Westphal M. Neuro-oncology of CNS tumors. Springer Verlag. (2006) ISBN:3540258337. Read it at Google Books - Find it at Amazon
- 2. David G. McLone. Pediatric Neurosurgery. Saunders. (2001) ISBN:072168209X. Read it at Google Books - Find it at Amazon
- 3. Lüders HO, Comair YG. Epilepsy Surgery. Lippincott Williams & Wilkins. (2001) ISBN:0781714427. Read it at Google Books - Find it at Amazon
- 4. Rees J, Wen PY. Neuro-oncology. Saunders. (2010) ISBN:0750675160. Read it at Google Books - Find it at Amazon
- 5. Lind-LandströM T, Habberstad AH, SundstrøM S et-al. Prognostic value of histological features in diffuse astrocytomas WHO grade II. Int J Clin Exp Pathol. 2012;5 (2): 152-8. Free text at pubmed - Pubmed citation
- 6. Louis DN, Perry A, Reifenberger G et-al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131 (6): 803-20. doi:10.1007/s00401-016-1545-1 - Pubmed citation
- WHO classification of CNS tumours
- WHO grading of CNS tumours
- VASARI MRI feature set
- diffuse astrocytoma grading
- grade I:
- grade II:
- grade III
- grade IV:
- glioblastoma vs cerebral metastasis
- radiation-induced gliomas
- gliomatosis cerebri (growth pattern)
- specific locations
- treatment response
- Stupp protocol
- glioma treatment response assessment in clinical trials
- multicentric glioblastoma
- multifocal glioblastoma
- prognostic genetic markers